Results of long-term follow-up of patients with superficial bladder carcinoma treated with intravesically applied bacillus Calmette-Guerin vaccine according to the schedule of 6 weekly + 6 monthly instillations.

Background: The efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in the prevention of local recurrence and disease progression in patients with superficial bladder cancer is very well documented. This study reports the effect of BCG on disease-specific and overall survival.

Patients And Methods: In this retrospective trial, we have analyzed 170 patients with stage Ta and T1 superficial bladder cancer.

[Lipomatosis pelvis].

The article is a discussion of three cases of lipomatosis in the pelvis and of the surgical treatment undertaken in each case. In the first two cases, fatty tissue compressed the lower uriunary tract, and in the third, the rectosigmoid intestine. In the third case, the patient was also diagnosed as having a malignant rectum polyp.

Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.

Aim: To evaluate the effect of intravesical instillation of Bacillus Calmette-Guerin (BCG) in the prevention of recurrence and progression of the superficial bladder cancer.

Methods: Between February 1989 and May 1994, 170 patients with histologically proven superficial transitional cell carcinoma of the bladder stage Ta and T1 were assessed as eligible for 6-week + 6-month protocol of intravesical BCG instillation at the Split University Hospital. All patients underwent complete transurethral resection of the tumor, which established tumor size, histology, stage, and absence of muscle invasion.